Cytokinetics dcf value
WebFeb 28, 2024 · The US FDA has issued a Complete Response Letter to Cytokinetics ( NASDAQ: CYTK) for omecamtiv mecarbil for heart failure with reduced ejection fraction. Shares are down ~8% in post-market... WebFeb 27, 2024 · Moment of Truth for Cytokinetics’ Heart Failure Drug On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction.
Cytokinetics dcf value
Did you know?
WebBased on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. Best Analysts Covering Cytokinetics Most Accurate Analysts WebFeb 15, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential...
WebCytokinetics Inc (NASDAQ:CYTK) DCF value calculation. Find out whether CYTK is … WebMar 31, 2024 · On Friday 03/03/2024 the closing price of the Cytokinetics Inc share was $41.95 on NAS. Compared to the opening price on Friday 03/03/2024 on NAS of $39.73, this is a gain of 5.29%. Cytokinetics ...
WebCYTK: Raising target price to $37.00 CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety... WebThe cytokinin zeatin is named after the genus of corn, Zea. Cytokinins ( CK) are a class …
WebCYTK Intrinsic Value: DCF (Dividends Based) as of today (August 12, 2024) is $0.00. In …
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by … chimfex lowesWebJul 19, 2024 · Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ... graduate certificate in women\u0027s healthWebApr 6, 2024 · Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.48 billion … graduate certificate in tesol griffithWebJun 5, 2024 · Cytokines are diverse and serve a number of functions in the body. They: … chimfex sdsWebFeb 17, 2024 · Cytokinetics stock was originally listed at a price of $97.56 in Apr 30, … graduate certificate in theology onlineWebMar 2, 2024 · Cytokinetics shares have risen in value by nearly 450% over the past five years - so shareholders have hardly had to deal with disappointment - even if the lead asset was ultimately rejected for ... chimfex reviewWebOct 25, 2024 · Cytokinetics expects that it will end 2024 with more than $800 million in cash. This, despite the fact that it expects that its operating expenses for all of 2024 to end up being in the range of ... graduate certificate of arts une